Literature DB >> 21104859

Bacterial overgrowth syndrome in myotonic muscular dystrophy is potentially treatable.

Mark A Tarnopolsky1, Erin Pearce, Andre Matteliano, Cindy James, David Armstrong.   

Abstract

Over one third of patients with myotonic muscular dystrophy type 1 (DM1) have gastrointestinal complaints. The cause is multifactorial, and treatment options are limited. Twenty DM1 patients with gastrointestinal symptoms were screened over a 2-year period using glucose breath hydrogen testing (GBHT) to evaluate the prevalence of small intestinal bacterial overgrowth (SIBO). Sixty-five percent of patients had a positive GBHT, and diarrhea was the most common presenting symptom. Ciprofloxacin was the most common antibiotic used for treatment, and 70% of patients reported a good response to the initial course of treatment. Although the causes of gastrointestinal symptoms in patients with DM1 are multifactorial, small intestinal bacterial overgrowth is an important diagnostic consideration that is easily diagnosed using glucose breath hydrogen testing and often shows a good response to treatment with common antibiotics.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21104859     DOI: 10.1002/mus.21787

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  7 in total

Review 1.  Congenital and childhood myotonic dystrophy: Current aspects of disease and future directions.

Authors:  Genevieve Ho; Michael Cardamone; Michelle Farrar
Journal:  World J Clin Pediatr       Date:  2015-11-08

Review 2.  Myotonic Dystrophies: Targeting Therapies for Multisystem Disease.

Authors:  Samantha LoRusso; Benjamin Weiner; W David Arnold
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

3.  The enteric nervous system promotes intestinal health by constraining microbiota composition.

Authors:  Annah S Rolig; Erika K Mittge; Julia Ganz; Josh V Troll; Ellie Melancon; Travis J Wiles; Kristin Alligood; W Zac Stephens; Judith S Eisen; Karen Guillemin
Journal:  PLoS Biol       Date:  2017-02-16       Impact factor: 8.029

4.  High Prevalence and Gender-Related Differences of Gastrointestinal Manifestations in a Cohort of DM1 Patients: A Perspective, Cross-Sectional Study.

Authors:  Alessia Perna; Daria Maccora; Salvatore Rossi; Tommaso Filippo Nicoletti; Maria Assunta Zocco; Vittorio Riso; Anna Modoni; Antonio Petrucci; Venanzio Valenza; Antonio Grieco; Luca Miele; Gabriella Silvestri
Journal:  Front Neurol       Date:  2020-06-12       Impact factor: 4.003

5.  High frequency of gastrointestinal manifestations in myotonic dystrophy type 1 and type 2.

Authors:  James E Hilbert; Richard J Barohn; Paula R Clemens; Elizabeth A Luebbe; William B Martens; Michael P McDermott; Amy L Parkhill; Rabi Tawil; Charles A Thornton; Richard T Moxley
Journal:  Neurology       Date:  2017-08-30       Impact factor: 9.910

Review 6.  Myotonic disorders: A review article.

Authors:  Chris Hahn; Mohammad Kian Salajegheh
Journal:  Iran J Neurol       Date:  2016-01-05

7.  Zebrafish mbnl mutants model physical and molecular phenotypes of myotonic dystrophy.

Authors:  Melissa N Hinman; Jared I Richardson; Rose A Sockol; Eliza D Aronson; Sarah J Stednitz; Katrina N Murray; J Andrew Berglund; Karen Guillemin
Journal:  Dis Model Mech       Date:  2021-06-14       Impact factor: 5.758

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.